Combining ulixertinib (ERK1/2 Inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAFV600E mutant colorectal cancer models

被引：1
|
作者：
Knoerzer, Deborah
Reddy, Anupama
Box, Jessica A.
Groover, Anna
Kreider, Brent
Teresk, Martin
Emery, Caroline M.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2693
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2693
引用
收藏
页数：2
相关论文
共 50 条
  • [31] RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
    Elena Elez
    Javier Ros
    Jose Fernández
    Guillermo Villacampa
    Ana Belén Moreno-Cárdenas
    Carlota Arenillas
    Kinga Bernatowicz
    Raquel Comas
    Shanshan Li
    David Philip Kodack
    Roberta Fasani
    Ariadna Garcia
    Javier Gonzalo-Ruiz
    Alejandro Piris-Gimenez
    Paolo Nuciforo
    Grainne Kerr
    Rossana Intini
    Aldo Montagna
    Marco Maria Germani
    Giovanni Randon
    Ana Vivancos
    Ron Smits
    Diana Graus
    Raquel Perez-Lopez
    Chiara Cremolini
    Sara Lonardi
    Filippo Pietrantonio
    Rodrigo Dienstmann
    Josep Tabernero
    Rodrigo A. Toledo
    Nature Medicine, 2022, 28 : 2162 - 2170
  • [32] RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
    Elez, Elena
    Ros, Javier
    Fernandez, Jose
    Villacampa, Guillermo
    Moreno-Cardenas, Ana Belen
    Arenillas, Carlota
    Bernatowicz, Kinga
    Comas, Raquel
    Li, Shanshan
    Kodack, David Philip
    Fasani, Roberta
    Garcia, Ariadna
    Gonzalo-Ruiz, Javier
    Piris-Gimenez, Alejandro
    Nuciforo, Paolo
    Kerr, Grainne
    Intini, Rossana
    Montagna, Aldo
    Germani, Marco Maria
    Randon, Giovanni
    Vivancos, Ana
    Smits, Ron
    Graus, Diana
    Perez-Lopez, Raquel
    Cremolini, Chiara
    Lonardi, Sara
    Pietrantonio, Filippo
    Dienstmann, Rodrigo
    Tabernero, Josep
    Toledo, Rodrigo A.
    NATURE MEDICINE, 2022, 28 (10) : 2162 - +
  • [33] Pre-treatment p-EGFR levels in tumors from a genetically engineered mouse model of BRAFV600E colorectal cancer predict response to combined BRAF/EGFR inhibition
    Coffee, Erin M.
    Corcoran, Ryan B.
    Engelman, Jeffrey A.
    CANCER RESEARCH, 2014, 74 (19)
  • [34] Erratum: Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model
    Daniel C. Kirouac
    Gabriele Schaefer
    Jocelyn Chan
    Mark Merchant
    Christine Orr
    Shih-Min A. Huang
    John Moffat
    Lichuan Liu
    Kapil Gadkar
    Saroja Ramanujan
    npj Systems Biology and Applications, 3
  • [35] Targeting CDK1 and MEK/ERK overcomes apoptosis resistance in BRAFV600E human colorectal cancer cells
    Zhang, Peng
    Kawakami, Hisato
    Liu, Weizhen
    Zeng, Xiangyu
    Stebhardt, Klaus
    Tao, Kaixiong
    Huang, Shengbing
    Sinicrope, Frank A.
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma
    Ngiow, Shin Foong
    Meeth, Katrina M.
    Stannard, Kimberley
    Barkauskas, Deborah S.
    Bollag, Gideon
    Bosenberg, Marcus
    Smyth, Mark J.
    ONCOIMMUNOLOGY, 2016, 5 (03):
  • [37] Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC)
    Wong, Vanessa
    Hong, Wei
    Ananda, Sumitra
    Dunn, Catherine
    Wong, Rachel
    To, Yat Hang
    Burge, Matthew E.
    Nott, Louise M.
    Tie, Jeanne
    Shapiro, Jeremy David
    Jennens, Ross
    Khattak, Muhammad Adnan
    Roohullah, Aflah
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [38] Differential contribution for ERK1 and ERK2 kinases in BRAFV600E-triggered phenotypes in adult mouse models
    Bosso, Giuseppe
    Herpst, Ana Carolina Cintra
    Laguia, Oscar
    Adetchessi, Sarah
    Serrano, Rosa
    Blasco, Maria A.
    CELL DEATH AND DIFFERENTIATION, 2024, 31 (06): : 804 - 819
  • [39] Clinical responses to ERK inhibition in BRAFV600E-mutant Colorectal Cancer Predicted Using a QSP-based Computational Model
    Kirouac, Daniel C.
    Schaeffer, Gabriele
    Chan, Jocelyn
    Merchant, Mark
    Orr, Christine
    Liu, Lichuan
    Huang, Alex
    Moffat, John
    Gadkar, Kapil
    Ramanujan, Saroja
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S23 - S23
  • [40] EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines
    Jia, Yongsheng
    Zhang, Cuicui
    Hu, Chuanxiang
    Yu, Yang
    Zheng, Xiangqian
    Li, Yigong
    Gao, Ming
    ONCOLOGY LETTERS, 2018, 15 (05) : 6763 - 6769
12345